<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-18T18:56:42Z</responseDate><request verb="GetRecord" identifier="oai:dora.dmu.ac.uk:2086/21127" metadataPrefix="uketd_dc">https://dora.dmu.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:dora.dmu.ac.uk:2086/21127</identifier><datestamp>2023-09-20T19:31:17Z</datestamp><setSpec>com_2086_2388</setSpec><setSpec>col_2086_2389</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Mechanistic Understanding of Co-crystal solubility and dissolution by using a combination of Experimental and Molecular Modelling Techniques</dc:title>
   <dc:creator>Kirubakaran, Preyanthiny</dc:creator>
   <dcterms:abstract>The purpose of this study is to improve the solubility, dissolution rate and permeability of poorly water-soluble drugs by understanding the mechanism of dissolution at molecular level of Flufenamic acid and Carbamazepine co-crystals in the presence of polymers. This study has been separated into four sections: (1) Formation of pharmaceutical co-crystals: Three pharmaceutical co-crystals of poorly water soluble active pharmaceutical ingredient (API) of Flufenamic acid (FFA) and Carbamazepine (CBZ) were synthesized, including 1:1 Flufenamic acid-theophylline co-crystal (FFATP CO), 1:1 Flufenamic acid-nicotinamide co-crystal (FFA-NIC CO) and 1:1 Carbamazepine-nicotinamide co-crystal (CBZ-NIC CO). The results of Fourier Transform Infrared spectroscopy (FTIR), Differential scanning calorimetry (DSC) and X-ray Powder Diffraction (XRPD) confirmed the formation of co-crystals. (2) The effect of polymers on the surface dissolution of co-crystals: The influence of three polymers (polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and a copolymer of N-vinly-2- pyrrolidone (60%) and vinyl acetate (40%) (PVP-VA)) on the surfaces of FFA-TP CO, FFA-NIC CO and CBZ-NIC CO was studied using Atomic force Microscopy (AFM), Scanning electron microscopy (SEM) and Raman spectroscopy. It was found that the co-crystals have different dissolution mechanisms, and that addition of polymers can alter the dissolution properties of co-crystals by interacting with the crystal faces. (3) The molecular interactions between the drugs, co-formers and polymers were investigated using Nuclear Magnetic Resonance (NMR) and Diffusion Ordered Spectroscopy (DOSY). It was found that the type of a polymer, its concentration, and the interaction of the polymer with a co-former in solution will significantly affect the FFA and CBZ co-crystals (4). Molecular modelling of free drug molecules with coformers and polymers in the presence of water molecules: Results indicate bulk precipitation could be occurring for FFA molecules in solution and that PVP-VA was an effective precipitation inhibitor for all three co-crystals studied in solution. Overall, PVP was an effective polymer for surface precipitation inhibitor and PVP-VA was the most effective inhibitor for precipitation in solution.</dcterms:abstract>
   <uketdterms:institution>De Montfort University</uketdterms:institution>
   <dcterms:issued>2021-01</dcterms:issued>
   <dc:type>Thesis or dissertation</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>PhD</uketdterms:qualificationname>
   <dc:language xsi:type="dcterms:ISO639-2">en</dc:language>
   <dcterms:isReferencedBy>https://dora.dmu.ac.uk/handle/2086/21127</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://dora.dmu.ac.uk/bitstreams/54b8f9be-05c4-4c4e-9714-5dfe0d54898d/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">957ce5e37996841c062039318170ac7f</uketdterms:checksum>
   <dcterms:license>https://dora.dmu.ac.uk/bitstreams/be963c5c-f5ab-407a-8f19-19064d8593fa/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">bd41181d9a4c38b5ebacc69a027024d9</uketdterms:checksum>
   <dcterms:hasFormat>https://dora.dmu.ac.uk/bitstreams/26967df4-a459-44bf-9c34-4a12d32fadde/download</dcterms:hasFormat>
   <uketdterms:checksum xsi:type="uketdterms:MD5">b0312873b14c252d42d32e0a5631e92e</uketdterms:checksum>
   <uketdterms:department>Faculty of Health and Life Sciences</uketdterms:department>
</uketd_dc:uketddc></metadata></record></GetRecord></OAI-PMH>